[Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines.]

[1]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[2]  J. Arenillas,et al.  Dyslipidemias and stroke prevention: recommendations of the Study Group of Cerebrovascular Diseases of the Spanish Society of Neurology. , 2020, Neurologia.

[3]  B. Fuentes,et al.  Dislipidemias y prevención del ictus: recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología , 2020, Neurología.

[4]  C. Jericó,et al.  Beneficios de la reducción del colesterol LDL en la prevención secundaria del ictus isquémico. Nuevas evidencias , 2020 .

[5]  C. Mathieu,et al.  Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) , 2020, Diabetologia.

[6]  Hong Wang,et al.  Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis , 2020, Stroke.

[7]  E. Vinyoles.  El control de la hipertensión arterial: precoz y diligente , 2020 .

[8]  J. Aranceta-bartrina,et al.  Prevalencia de sobrepeso, obesidad y obesidad abdominal en población española entre 3 y 24 años. Estudio ENPE , 2020 .

[9]  J. Boer,et al.  Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. , 2020, European heart journal.

[10]  Nancy Babio,et al.  Impacto de Life's Simple 7 en la incidencia de eventos cardiovasculares mayores en adultos españoles con alto riesgo de la cohorte del estudio PREDIMED , 2020 .

[11]  J. M. Vázquez,et al.  La prevención primordial, primordial en la prevención cardiovascular , 2020 .

[12]  E. Vicaut,et al.  Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke , 2020, Stroke.

[13]  E. Vinyoles.  [Controlling high blood pressure: Early and diligent]. , 2020 .

[14]  L. G. Vu,et al.  Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2020, The Lancet.

[15]  Francesca N. Delling,et al.  Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association , 2020, Circulation.

[16]  G. Filippatos,et al.  2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2020, European heart journal.

[17]  Deepak L. Bhatt,et al.  Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. , 2020, Journal of the American College of Cardiology.

[18]  A. Keech,et al.  Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. , 2020, The lancet. Diabetes & endocrinology.

[19]  11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020 , 2019, Diabetes Care.

[20]  A. Hoes,et al.  Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology* , 2019, European journal of preventive cardiology.

[21]  Panos Vardas,et al.  European Society of Cardiology: Cardiovascular Disease Statistics 2019. , 2019, European heart journal.

[22]  E. Vicaut,et al.  A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. , 2019, The New England journal of medicine.

[23]  D. Panagiotakos,et al.  Exposure to second hand smoke and 10-year (2002-2012) incidence of cardiovascular disease in never smokers: The ATTICA cohort study. , 2019, International journal of cardiology.

[24]  A. Bueno-Cavanillas,et al.  [Food policies to prevent obesity and the main non-transmissible diseases in Spain: where there's a will there's a way]. , 2019, Gaceta sanitaria.

[25]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[26]  C. Wee,et al.  Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease in the United States: Results From the 2017 National Health Interview Survey , 2019, Annals of Internal Medicine.

[27]  F. Cosentino,et al.  The 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. , 2019, European heart journal.

[28]  A. Goette,et al.  Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial , 2019, The Lancet.

[29]  S. Yusuf,et al.  A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial , 2019, The Lancet.

[30]  S. L. Muñoz,et al.  [Validation of the SCORE index and SCORE for old people in the Castilla y Léon cardiovascular disease risk cohort]. , 2019, Hipertension y riesgo vascular.

[31]  J. Banegas,et al.  [Position statement on ambulatory blood pressure monitoring (ABPM) by the Spanish Society of Hypertension (2019)]. , 2019, Hipertension y riesgo vascular.

[32]  J. Pell,et al.  Glomerular filtration rate by differing measures, albuminuria and prediction of cardiovascular disease, mortality and end-stage kidney disease , 2019, Nature Medicine.

[33]  R. Jackson,et al.  Personalized Prediction of Cardiovascular Benefits and Bleeding Harms From Aspirin for Primary Prevention , 2019, Annals of Internal Medicine.

[34]  Deepak L. Bhatt,et al.  Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome , 2019, Journal of the American College of Cardiology.

[35]  A. Khera,et al.  2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[36]  Antonio Gasparrini,et al.  Ambient Particulate Air Pollution and Daily Mortality in 652 Cities. , 2019, The New England journal of medicine.

[37]  V. Pasceri,et al.  Meta-Regression to Identify Patients Deriving the Greatest Benefit from Dual Antiplatelet Therapy after Stroke or Transient Ischemic Attack Without Thrombolytic or Thrombectomy Treatment. , 2019, The American journal of cardiology.

[38]  A. Navar,et al.  The Association Between Low‐Density Lipoprotein Cholesterol and Incident Atherosclerotic Cardiovascular Disease in Older Adults: Results From the National Institutes of Health Pooled Cohorts , 2019, Journal of the American Geriatrics Society.

[39]  Deepak L. Bhatt,et al.  Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. , 2019, Journal of the American College of Cardiology.

[40]  D. Grobbee,et al.  Accreditation of clinical centres providing primary prevention, secondary prevention and rehabilitation, and sports cardiology: A step towards optimizing quality , 2019, European journal of preventive cardiology.

[41]  J. Coste,et al.  Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France , 2019, European heart journal.

[42]  D. Fernández,et al.  Estimation of Lifetime Risk of Cardiovascular Disease (IBERLIFERISK): A New Tool for Cardiovascular Disease Prevention in Primary Care. , 2019, Revista espanola de cardiologia.

[43]  D. Verloo,et al.  Food Safety Regulatory Research Needs 2030 , 2019, EFSA journal. European Food Safety Authority.

[44]  F. Rodríguez‐Artalejo,et al.  Impact of the European and American guidelines on hypertension prevalence, treatment, and cardiometabolic goals. , 2019, Journal of hypertension.

[45]  C. Brotons,et al.  Estimación del riesgo cardiovascular de por vida (IBERLIFERISK): una herramienta nueva en prevención primaria de las enfermedades cardiovasculares , 2019, Revista Española de Cardiología.

[46]  F. Vermassen,et al.  Global Vascular Guidelines on the Management of Chronic Limb-Threatening Ischemia. , 2019, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[47]  S. Hoffman,et al.  Impact of the WHO Framework Convention on Tobacco Control on global cigarette consumption: quasi-experimental evaluations using interrupted time series analysis and in-sample forecast event modelling , 2019, BMJ.

[48]  M. Buman,et al.  Physical Activity Promotion: Highlights from the 2018 Physical Activity Guidelines Advisory Committee Systematic Review , 2019, Medicine and science in sports and exercise.

[49]  W. Kraus,et al.  Physical Activity, All-Cause and Cardiovascular Mortality, and Cardiovascular Disease , 2019, Medicine and science in sports and exercise.

[50]  W. Kraus,et al.  High-Intensity Interval Training for Cardiometabolic Disease Prevention , 2019, Medicine and science in sports and exercise.

[51]  E. Fisher,et al.  Cardiovascular Risk Factor Control and Lifestyle Factors in Young to Middle-Aged Adults with Newly Diagnosed Obstructive Coronary Artery Disease , 2019, Cardiology.

[52]  N. Sattar,et al.  Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks: Findings From the Swedish National Diabetes Registry , 2019, Circulation.

[53]  L. Masana,et al.  Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA), 2019. , 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

[54]  N. Plana,et al.  Effect of lipid-lowering treatment in cardiovascular disease prevalence in familial hypercholesterolemia. , 2019, Atherosclerosis.

[55]  L. G. Vu,et al.  Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2019, The Lancet.

[56]  C. Cervantes,et al.  Posicionamiento para el manejo de la hipertensión arterial en atención primaria a partir del análisis crítico de las guías americana (2017) y europea (2018). Sociedad Española de Médicos de Atención Primaria (SEMERGEN) , 2019, Medicina de Familia. SEMERGEN.

[57]  P. Gately,et al.  Prevalence of Severe Obesity among Primary School Children in 21 European Countries , 2019, Obesity Facts.

[58]  Marc P. Bonaca,et al.  Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials , 2019, Circulation.

[59]  T. Strandberg,et al.  Hypertension Management in Older and Frail Older Patients , 2019, Circulation research.

[60]  Ulrich Pöschl,et al.  Cardiovascular disease burden from ambient air pollution in Europe reassessed using novel hazard ratio functions , 2019, European heart journal.

[61]  C. Herrmann-Lingen,et al.  Additional effects of psychological interventions on subjective and objective outcomes compared with exercise-based cardiac rehabilitation alone in patients with cardiovascular disease: A systematic review and meta-analysis , 2019, European journal of preventive cardiology.

[62]  Diederick Grobbee,et al.  Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry , 2019, European journal of preventive cardiology.

[63]  John Fuller,et al.  Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials , 2019, The Lancet.

[64]  W. Willett,et al.  Food in the Anthropocene: the EAT–Lancet Commission on healthy diets from sustainable food systems , 2019, The Lancet.

[65]  E. Vinyoles,et al.  The prognostic value of blood pressure control delay in newly diagnosed hypertensive patients , 2019, Journal of hypertension.

[66]  A. Quyyumi,et al.  Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation developed under the auspices of the ESC Committee for Practice Guidelines. , 2019, European heart journal.

[67]  B. Freedman,et al.  Telehealth interventions for the secondary prevention of coronary heart disease: A systematic review and meta-analysis , 2019, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[68]  B. Davis,et al.  Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. , 2019, European heart journal.

[69]  C. Faselis,et al.  Is very low LDL-C harmful? , 2019, Current pharmaceutical design.

[70]  Alberto Ortiz,et al.  The Spanish Society of Nephrology (SENEFRO) commentary to the Spain GBD 2016 report: Keeping chronic kidney disease out of sight of health authorities will only magnify the problem. , 2019, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[71]  M. Basha,et al.  Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia , 2019, Journal of the Practice of Cardiovascular Sciences.

[72]  G. Guyatt,et al.  Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis , 2018, British Medical Journal.

[73]  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2019 , 2018, Diabetes Care.

[74]  F. Song,et al.  Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. , 2018, The Cochrane database of systematic reviews.

[75]  S. Carlson,et al.  The Physical Activity Guidelines for Americans , 2018, JAMA.

[76]  Odyssey Outcomes Investigators.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018 .

[77]  Y. Fukumoto,et al.  Association between physical activity, occupational sitting time and mortality in a general population: An 18-year prospective survey in Tanushimaru, Japan , 2018, European journal of preventive cardiology.

[78]  Madhu Sudhan Atteraya,et al.  Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[79]  R. Collins,et al.  Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus , 2018, The New England journal of medicine.

[80]  Geltrude Mingrone,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetes Care.

[81]  Thomas Kahan,et al.  [2018 ESC/ESH Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH)]. , 2018, Giornale italiano di cardiologia.

[82]  J. Car,et al.  Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). , 2018, Atherosclerosis.

[83]  S. Pettigrew,et al.  Objective Understanding of Front-of-Package Nutrition Labels: An International Comparative Experimental Study across 12 Countries , 2018, Nutrients.

[84]  Danielle E. Clarkesmith,et al.  Effectiveness of Cognitive Behavioral Therapy for Depression and Anxiety in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis , 2018, Psychosomatic medicine.

[85]  Suzanne G. Orchard,et al.  Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly , 2018, The New England journal of medicine.

[86]  E. V. van Beek,et al.  Coronary CT Angiography and 5‐Year Risk of Myocardial Infarction , 2018, The New England journal of medicine.

[87]  J. Marrugat,et al.  Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study , 2018, British Medical Journal.

[88]  C. Wolfson,et al.  Screening and treatment of hypertension in older adults: less is more? , 2018, Public Health Reviews.

[89]  P. Rothwell,et al.  Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial , 2018, The Lancet.

[90]  Josep Maria Haro,et al.  La carga de enfermedad en España: resultados del Estudio de la Carga Global de las Enfermedades 2016 , 2018, Medicina Clínica.

[91]  G. Lip,et al.  2018 ESC/ESH Guidelines for the management of arterial hypertension. , 2018, European heart journal.

[92]  A. Keech,et al.  Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[93]  A. Hattersley,et al.  Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study , 2018, The Lancet.

[94]  Jennifer S. Lin,et al.  Nontraditional Risk Factors in Cardiovascular Disease Risk Assessment: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2018, JAMA.

[95]  J. R. Banegas,et al.  Estudio de mortalidad del Registro español de monitorización ambulatoria de la presión arterial. Una llamada a la traslación de la monitorización ambulatoria de la presión arterial a la práctica clínica , 2018, Hipertensión y Riesgo Vascular.

[96]  Mark J. Nieuwenhuijsen,et al.  Influence of urban and transport planning and the city environment on cardiovascular disease , 2018, Nature Reviews Cardiology.

[97]  Mohammed K. Ali,et al.  Global Diabetes Prevention Interventions: A Systematic Review and Network Meta-analysis of the Real-World Impact on Incidence, Weight, and Glucose , 2018, Diabetes Care.

[98]  Dirk De Bacquer,et al.  Determinants of participation and risk factor control according to attendance in cardiac rehabilitation programmes in coronary patients in Europe: EUROASPIRE IV survey , 2018, European journal of preventive cardiology.

[99]  G. Lip,et al.  Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence , 2018, European heart journal.

[100]  Jian‐Jun Li,et al.  Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new‐onset diabetes mellitus and glucose metabolism: A systematic review and meta‐analysis , 2018, Diabetes, obesity & metabolism.

[101]  R. Conwit,et al.  Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA , 2018, The New England journal of medicine.

[102]  Jackson T. Wright,et al.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2018, Journal of the American College of Cardiology.

[103]  L. Poston,et al.  Before the beginning: nutrition and lifestyle in the preconception period and its importance for future health , 2018, The Lancet.

[104]  J. De Sutter,et al.  Economic and social impact of increased cardiac rehabilitation uptake and cardiac telerehabilitation in Belgium – a cost–benefit analysis , 2018, Acta cardiologica.

[105]  W. Kostis,et al.  Effect of cholesterol lowering with statins or proprotein convertase subtilisin/kexin type 9 antibodies on cataracts: A meta-analysis. , 2018, Journal of clinical lipidology.

[106]  R. D. de Boer,et al.  Novel heart failure biomarkers: why do we fail to exploit their potential? , 2018, Critical reviews in clinical laboratory sciences.

[107]  William J. Astle,et al.  Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies , 2018, The Lancet.

[108]  Seamus Byrne,et al.  A Child Rights-Based Approach to Food Marketing A Guide for Policy Makers , 2018 .

[109]  Daniel E Jonas,et al.  Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis , 2018, Circulation. Cardiovascular quality and outcomes.

[110]  S. Hercberg,et al.  Front-of-pack Nutri-Score labelling in France: an evidence-based policy. , 2018, The Lancet. Public health.

[111]  Theresa M. Beckie,et al.  2018 ACC/AHA Clinical Performance and Quality Measures for Cardiac Rehabilitation: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. , 2018, Journal of the American College of Cardiology.

[112]  F. Formiga,et al.  [Treatment of type 2 diabetes mellitus in elderly patients]. , 2018, Revista espanola de geriatria y gerontologia.

[113]  J. Shaw,et al.  Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997–2011 , 2018, Diabetologia.

[114]  P. Muntner,et al.  Response to Letter to editor "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults". , 2018, Journal of the American Society of Hypertension : JASH.

[115]  L. Neubeck,et al.  Effectiveness, acceptability and usefulness of mobile applications for cardiovascular disease self-management: Systematic review with meta-synthesis of quantitative and qualitative data , 2018, European journal of preventive cardiology.

[116]  N. Sattar,et al.  Short-term progression of cardiometabolic risk factors in relation to age at type 2 diabetes diagnosis: a longitudinal observational study of 100,606 individuals from the Swedish National Diabetes Register , 2018, Diabetologia.

[117]  M. Woodward,et al.  Women’s reproductive factors and incident cardiovascular disease in the UK Biobank , 2018, Heart.

[118]  C. Jennison,et al.  Rates of glycaemic deterioration in a real-world population with type 2 diabetes , 2017, Diabetologia.

[119]  A. Briggs,et al.  ‘Highest risk–highest benefit’ strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies , 2017, European heart journal.

[120]  Roy Taylor,et al.  Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial , 2017, The Lancet.

[121]  Philip D. Harvey,et al.  No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data , 2017, European heart journal.

[122]  Marc P. Bonaca,et al.  Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) , 2017, Circulation.

[123]  J. Gaziano,et al.  Statins for Primary Prevention of Cardiovascular Events and Mortality in Older Men , 2017, Journal of the American Geriatrics Society.

[124]  B. Vaes,et al.  Association between traditional cardiovascular risk factors and mortality in the oldest old: untangling the role of frailty , 2017, BMC Geriatrics.

[125]  N. M. Nasir,et al.  Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. , 2017, The lancet. Diabetes & endocrinology.

[126]  D. Nathan,et al.  The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study , 2017, Diabetologia.

[127]  R. Giugliano,et al.  Prevention of Stroke with the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) , 2017, Circulation.

[128]  M. Bots,et al.  Preventing cardiovascular disease after hypertensive disorders of pregnancy: Searching for the how and when , 2017, European journal of preventive cardiology.

[129]  V. Llorente-Cortés,et al.  Biomarcadores epigenéticos y enfermedad cardiovascular: los microARN circulantes , 2017 .

[130]  Deepak L. Bhatt,et al.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation , 2017, The New England journal of medicine.

[131]  K. Bibbins-Domingo,et al.  Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial , 2017, JAMA.

[132]  A. Keech,et al.  Cognitive Function in a Randomized Trial of Evolocumab , 2017, The New England journal of medicine.

[133]  S. Bangalore,et al.  Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. , 2017, The American journal of medicine.

[134]  C. Free,et al.  Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults. , 2017, The Cochrane database of systematic reviews.

[135]  J. Hippisley-Cox,et al.  Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study , 2017, British Medical Journal.

[136]  D. De Bacquer,et al.  Psychosocial risk factors in relation to other cardiovascular risk factors in coronary heart disease: Results from the EUROASPIRE IV survey. A registry from the European Society of Cardiology , 2017, European journal of preventive cardiology.

[137]  Juan P Casas,et al.  Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. , 2017, The Cochrane database of systematic reviews.

[138]  J. García,et al.  Evaluación de la validez de las funciones SCORE de bajo riesgo y calibrada para población española en las cohortes FRESCO , 2017 .

[139]  G. Giovino,et al.  Implementation of key demand-reduction measures of the WHO Framework Convention on Tobacco Control and change in smoking prevalence in 126 countries: an association study. , 2017, The Lancet. Public health.

[140]  O. Descamps,et al.  How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment. , 2017, Atherosclerosis. Supplements.

[141]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[142]  P. Ponikowski,et al.  Cardiovascular Efficacy and Safety of Bococizumab in High‐Risk Patients , 2017, The New England journal of medicine.

[143]  M. Fornage,et al.  Heart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association , 2017, Circulation.

[144]  M. Woodward,et al.  Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare , 2017, Heart.

[145]  F. Álvarez,et al.  [Spanish adaptation of the 2016 European Guidelines on cardiovascular disease prevention in clinical practice]. , 2017, Gaceta sanitaria.

[146]  Z. Qin,et al.  The association between periodontal disease and the risk of myocardial infarction: a pooled analysis of observational studies , 2017, BMC Cardiovascular Disorders.

[147]  Jorge E. Palacios,et al.  Internet-Delivered Self-management Support for Improving Coronary Heart Disease and Self-management–Related Outcomes , 2017, The Journal of cardiovascular nursing.

[148]  W. Koenig,et al.  Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. , 2016, JAMA.

[149]  Mark D. Huffman,et al.  Global tobacco prevention and control in relation to a cardiovascular health promotion and disease prevention framework: A narrative review. , 2016, Preventive medicine.

[150]  G. Lip,et al.  Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. , 2016, The New England journal of medicine.

[151]  Morten Wang Fagerland,et al.  Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonised meta-analysis of data from more than 1 million men and women , 2016, The Lancet.

[152]  M. Marcus,et al.  Effect of Wearable Technology Combined With a Lifestyle Intervention on Long-term Weight Loss: The IDEA Randomized Clinical Trial. , 2016, JAMA.

[153]  Lenore J Launer,et al.  Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in Adults Aged ≥75 Years: A Randomized Clinical Trial. , 2016, JAMA.

[154]  Deepak L. Bhatt,et al.  Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease. , 2016, Journal of the American College of Cardiology.

[155]  Jackson T. Wright,et al.  A Randomized Trial of Intensive versus Standard Blood-Pressure Control. , 2016, The New England journal of medicine.

[156]  R. Peters,et al.  The telephone lifestyle intervention ‘Hartcoach’ has modest impact on coronary risk factors: A randomised multicentre trial , 2016, European journal of preventive cardiology.

[157]  C. Cowie,et al.  Risk Factors for Cardiovascular Disease in Type 1 Diabetes , 2016, Diabetes.

[158]  A. Romain,et al.  Efficacy of theory-based interventions to promote physical activity. A meta-analysis of randomised controlled trials , 2016, Health psychology review.

[159]  A. Jaffe,et al.  Biomarkers in heart failure: the importance of inconvenient details , 2015, ESC heart failure.

[160]  J. Fernandez-Solà.  Cardiovascular risks and benefits of moderate and heavy alcohol consumption , 2015, Nature Reviews Cardiology.

[161]  J. Catanese,et al.  Risk prediction by genetic risk scores for coronary heart disease is independent of self-reported family history , 2015, European heart journal.

[162]  J. Boucher,et al.  Lifestyle weight-loss intervention outcomes in overweight and obese adults with type 2 diabetes: a systematic review and meta-analysis of randomized clinical trials. , 2015, Journal of the Academy of Nutrition and Dietetics.

[163]  M. Woodward,et al.  Kidney measures beyond traditional risk factors for cardiovascular prediction: A collaborative meta-analysis , 2015, The lancet. Diabetes & endocrinology.

[164]  Improve-It Investigators.  Ezetimibe added to statin therapy after acute coronary syndromes , 2015 .

[165]  H. Kirshner,et al.  Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. , 2015, JAMA.

[166]  M. Woodward,et al.  Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. , 2015, The lancet. Diabetes & endocrinology.

[167]  Aurelio Tobías,et al.  Health impact assessment of traffic noise in Madrid (Spain). , 2015, Environmental research.

[168]  A. Rosengren,et al.  Glycemic control and excess mortality in type 1 diabetes. , 2014, The New England journal of medicine.

[169]  Longjiang Li,et al.  Periodontal therapy for the management of cardiovascular disease in patients with chronic periodontitis. , 2014, The Cochrane database of systematic reviews.

[170]  Diane Lacaille,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk , 2014 .

[171]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[172]  Paul Dendale,et al.  Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery , 2014, European journal of preventive cardiology.

[173]  J. Dai,et al.  Effects of Omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. , 2014, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[174]  Isaac Subirana,et al.  Derivation and validation of a set of 10-year cardiovascular risk predictive functions in Spain: the FRESCO Study. , 2014, Preventive medicine.

[175]  Mark D. Johnson,et al.  Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomised trial , 2014, The Lancet.

[176]  João Rodrigo Maciel Portes,et al.  The child with Down syndrome: risk and protective factors from the perspective of the Bioecological Theory of Human Development , 2013 .

[177]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[178]  Hayden McRobbie,et al.  Electronic cigarettes for smoking cessation: a randomised controlled trial , 2013, The Lancet.

[179]  H. P. van der Ploeg,et al.  Daily Sitting Time and All-Cause Mortality: A Meta-Analysis , 2013, PloS one.

[180]  A. Lucia,et al.  Exercise is the real polypill. , 2013, Physiology.

[181]  Liping Liu,et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.

[182]  M. Viana,et al.  Health effects from Sahara dust episodes in Europe: literature review and research gaps. , 2012, Environment international.

[183]  N. Skolnik,et al.  Management of Hyperglycemia in Type 2 Diabetes , 2012 .

[184]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[185]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[186]  Benjamin Willis,et al.  Lifetime risks for cardiovascular disease mortality by cardiorespiratory fitness levels measured at ages 45, 55, and 65 years in men. The Cooper Center Longitudinal Study. , 2011, Journal of the American College of Cardiology.

[187]  Deepak L. Bhatt,et al.  Effect of Clopidogrel plus ASA vs. ASA Early after TIA and Ischaemic Stroke: A Substudy of the CHARISMA Trial , 2011, International journal of stroke : official journal of the International Stroke Society.

[188]  Rena R Wing,et al.  Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. , 2010, Archives of internal medicine.

[189]  James M. Wright,et al.  Treatment of hypertension in patients 80 years and older: the lower the better? A meta-analysis of randomized controlled trials , 2010, Journal of hypertension.

[190]  M. Woodward,et al.  Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis , 2010, The Lancet.

[191]  A. Peters,et al.  Particulate Matter Air Pollution and Cardiovascular Disease: An Update to the Scientific Statement From the American Heart Association , 2010, Circulation.

[192]  D. Mozaffarian,et al.  Defining and Setting National Goals for Cardiovascular Health Promotion and Disease Reduction: The American Heart Association's Strategic Impact Goal Through 2020 and Beyond , 2010, Circulation.

[193]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[194]  C. Bouchard,et al.  Sitting time and mortality from all causes, cardiovascular disease, and cancer. , 2009, Medicine and science in sports and exercise.

[195]  M. J. Medrano,et al.  Riesgo coronario atribuible a los factores de riesgo cardiovascular en población española , 2007 .

[196]  Ralph B D'Agostino,et al.  EVIDENCE BASED PUBLIC HEALTH POLICY AND PRACTICE Validity of an adaptation of the Framingham cardiovascular risk function: the VERIFICA study , 2006 .

[197]  Dariush Mozaffarian,et al.  Fish intake, contaminants, and human health: evaluating the risks and the benefits. , 2006, JAMA.

[198]  Ross T Tsuyuki,et al.  A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.

[199]  B. Zinman,et al.  Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.

[200]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[201]  H. Tunstall-Pedoe,et al.  Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. , 2003, European heart journal.

[202]  J. Marrugat,et al.  Estimación del riesgo coronario en España mediante la ecuación de Framingham calibrada , 2003 .

[203]  T. Valle,et al.  Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. , 2001, The New England journal of medicine.

[204]  A. Parant.  [World population prospects]. , 1990, Futuribles.

[205]  C. Kase,et al.  U.S. Department of Health and Human Services , 2020 .

[206]  P. Gately,et al.  Mapping the health system response to childhood obesity in the WHO European Region , 2019 .

[207]  Miguel Ángel Royo Bordonada.  La publicidad que nos engorda , 2019 .

[208]  M. Woodward,et al.  Effects of blood pressure lowering on cardiovascular events, in the context of regression to the mean: a systematic review of randomized trials , 2019, Journal of hypertension.

[209]  A. Pries,et al.  Depression and coronary heart disease: 2018 ESC position paper of the working group of coronary pathophysiology and microcirculation developed under the auspices of the ESC Committee for Practice Guidelines , 2019 .

[210]  F. Rodríguez‐Artalejo,et al.  [Food policies to prevent obesity and the main non-transmissible diseases in Spain: where there's a will there's a way]. , 2019 .

[211]  J. Górriz,et al.  [Positioning for the management of arterial hypertension in Primary Care from the critical analysis of the American (2017) and European (2018) guidelines. Spanish Society of Primary Care Physicians (SEMERGEN)]. , 2019, Semergen.

[212]  J. Marsal,et al.  Short-term exposure to air pollutants increases the risk of ST elevation myocardial infarction and of infarct-related ventricular arrhythmias and mortality. , 2018, International journal of cardiology.

[213]  J. Bosch,et al.  Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. , 2018, Lancet.

[214]  A. Danese,et al.  Childhood and Adolescent Adversity and Cardiometabolic Outcomes: A Scientific Statement From the American Heart Association , 2018, Circulation.

[215]  P. Kolh,et al.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. , 2018, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[216]  J. Banegas,et al.  [Mortality study from the Spanish Registry of ABPM. An appeal for the transition of ABPM to clinical practice]. , 2018, Hipertension y riesgo vascular.

[217]  D. Alexander,et al.  A Meta‐Analysis of Randomized Controlled Trials and Prospective Cohort Studies of Eicosapentaenoic and Docosahexaenoic Long‐Chain Omega‐3 Fatty Acids and Coronary Heart Disease Risk , 2017, Mayo Clinic proceedings.

[218]  W. Campbell,et al.  Total red meat intake of ≥0.5 servings/d does not negatively influence cardiovascular disease risk factors: a systemically searched meta-analysis of randomized controlled trials. , 2017, The American journal of clinical nutrition.

[219]  Elizabeth M Webber,et al.  Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2016 .

[220]  C. Escobar Cervantes,et al.  [A randomized trial of intensive versus standard blood pressure control]. , 2016, Semergen.

[221]  A. Hoes,et al.  2016 European Guidelines on cardiovascular disease prevention in clinical practice. , 2016, Revista espanola de cardiologia.

[222]  J. Hipp,et al.  The impact of interventions to promote physical activity in urban green space: a systematic review and recommendations for future research. , 2015, Social science & medicine.

[223]  R. Califf,et al.  Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. , 2015, The New England journal of medicine.

[224]  B. Lushniak,et al.  The Health consequences of smoking—50 years of progress : a report of the Surgeon General , 2014 .

[225]  N. Pogosova,et al.  [Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery]. , 2014, Kardiologiia.

[226]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[227]  Victoria Morín Fraile.  Promoción de la actividad física , 2013 .

[228]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword , 2013 .

[229]  M. McLaughlin,et al.  Review of cardiovascular risk factors in women. , 2009, Gender medicine.

[230]  R. Collins,et al.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. , 2009, Lancet.

[231]  R. Becker,et al.  Low-dose aspirin in patients with stable cardiovascular disease: a meta-analysis. , 2008, The American journal of medicine.

[232]  A. Hoes,et al.  [Guidelines on cardiovascular disease prevention in clinical practice]. , 2005, Revue medicale de Liege.

[233]  S. Colagiuri,et al.  The Diabetes Control and Complications Trial , 1983, Henry Ford Hospital medical journal.

[234]  W. G. Walker,et al.  Plasma aldosterone regulation in anephric man. , 1973, Kidney international.